Myrcludex B is a novel drug candidate potentially useful for treatment of chronic hepatitis B (CHB) and chronic hepatitis delta (CHD). Myrcludex B was developed by Prof. Stephan Urban (University of Heidelberg, Germany). The group has access to unique tools to investigate entry events of hepatitis B virus (HBV).
It is the single representative of a novel class of anti-HBV molecules, entry inhibitors. Its mechanism of antiviral action is the highly specific, highly stable binding and inactivation of HBV receptors NTCP, which misdirects HBV to an unproductive pathway and thereby prevents an infection of the cell. This mechanism of action offers the possibility to address the two most important medical needs, namely long-term HBV eradication as well as antiviral activity against hepatitis delta virus (HDV).
Myrcludex B is a linear 47-amino acid chemically synthesized peptide bearing an N-terminal myristoyl moiety and a C-terminal carboxamide. It is composed of naturally occurring L-amino acids and is derived from the N-terminal domain of the large HBV surface protein. The drug has shown the potential to inhibit HBV and HDV spread in vitro, in animal models, and in clinical trials. Myrcludex B is manufactured by solid phase chemical synthesis, the process and analytical methods have been successfully established.